MA47231A - Conjugués anticorps-médicament pour l'ablation de cellules souches hématopoïétiques - Google Patents

Conjugués anticorps-médicament pour l'ablation de cellules souches hématopoïétiques

Info

Publication number
MA47231A
MA47231A MA047231A MA47231A MA47231A MA 47231 A MA47231 A MA 47231A MA 047231 A MA047231 A MA 047231A MA 47231 A MA47231 A MA 47231A MA 47231 A MA47231 A MA 47231A
Authority
MA
Morocco
Prior art keywords
antibody
stem cell
hematopoietic stem
drug conjugates
cell ablation
Prior art date
Application number
MA047231A
Other languages
English (en)
Inventor
Anthony E Boitano
Matthew Burger
Susan E Cellitti
Michael P Cooke
Catrin Finner
Bernhard Hubert Geierstanger
Yunho Jin
Si Tuen Lee-Hoeflich
Hongngoc Thi Pham
Siew Ho Schleyer
Kathrin Tissot
Tetsuo Uno
Ben Wen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA47231A publication Critical patent/MA47231A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA047231A 2016-12-21 2017-12-19 Conjugués anticorps-médicament pour l'ablation de cellules souches hématopoïétiques MA47231A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437622P 2016-12-21 2016-12-21
US201762520854P 2017-06-16 2017-06-16

Publications (1)

Publication Number Publication Date
MA47231A true MA47231A (fr) 2019-10-30

Family

ID=60957364

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047231A MA47231A (fr) 2016-12-21 2017-12-19 Conjugués anticorps-médicament pour l'ablation de cellules souches hématopoïétiques

Country Status (24)

Country Link
US (3) US11357864B2 (fr)
EP (1) EP3558389A1 (fr)
JP (2) JP7181203B2 (fr)
KR (2) KR20190099238A (fr)
CN (2) CN110099697B (fr)
AU (1) AU2017383458C1 (fr)
BR (1) BR112019012483A2 (fr)
CA (1) CA3045592A1 (fr)
CL (1) CL2019001745A1 (fr)
CO (1) CO2019006455A2 (fr)
CR (1) CR20190296A (fr)
CU (1) CU24644B1 (fr)
EA (1) EA201991526A1 (fr)
EC (1) ECSP19044625A (fr)
IL (2) IL300567A (fr)
JO (1) JOP20190155A1 (fr)
MA (1) MA47231A (fr)
MX (1) MX2019007582A (fr)
MY (1) MY193985A (fr)
PE (1) PE20191539A1 (fr)
PH (1) PH12019501330A1 (fr)
SA (1) SA519402188B1 (fr)
TW (2) TWI852077B (fr)
WO (1) WO2018116178A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015018899B1 (pt) * 2013-02-08 2023-09-26 Novartis Ag Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira
US10464969B2 (en) * 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
KR20230066647A (ko) * 2016-06-17 2023-05-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
CN112566671A (zh) * 2018-06-07 2021-03-26 美真达治疗公司 使用抗体药物缀合物(adc)的治疗方法
TW202014209A (zh) * 2018-06-20 2020-04-16 瑞士商諾華公司 用於消融造血幹細胞之抗體藥物軛合物
JP2021532116A (ja) * 2018-07-23 2021-11-25 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
JP7598312B2 (ja) * 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
EP3873930A4 (fr) * 2018-10-23 2022-12-07 Magenta Therapeutics, Inc. Conjugués anticorps-médicament (adc) à région fc mise sous silence et utilisations associées
US20230053449A1 (en) * 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
AU2019386976B2 (en) 2018-11-26 2024-05-30 Forty Seven, LLC Humanized antibodies against c-Kit
EP3894387A4 (fr) 2018-12-12 2023-07-19 Levim Biotech LLP Procédé d'acylation pour la préparation de peptide n-substitué
WO2020247670A1 (fr) 2019-06-04 2020-12-10 Magenta Therapeutics, Inc. Procédés et compositions pour le traitement de maladies auto-immunes
AU2019341066B1 (en) 2019-08-07 2021-04-01 Mabplex International Co., Ltd. Antibody-drug conjugates and uses thereof
CN116183899B (zh) * 2023-04-28 2023-06-30 天津市协和医药科技集团有限公司 一种吖啶酯标记抗体保存液的制备方法
TW202513593A (zh) * 2023-09-08 2025-04-01 大陸商信達生物製藥（蘇州）有限公司 半胱胺酸改造的抗體和免疫綴合物
WO2025080282A1 (fr) * 2023-10-12 2025-04-17 Memorial Sloan-Kettering Cancer Center Polythérapie avec des inhibiteurs de clk/dyrk et des inhibiteurs de bcl2 pour traiter la leucémie

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2109528A1 (fr) 1991-05-01 1992-11-02 Gregory A. Prince Methode de traitement des maladies respiratoires infectieuses
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2277801C (fr) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation de particules pour inhalation
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
WO1998056915A2 (fr) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
CA2336139C (fr) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2476166C (fr) 2002-02-14 2011-11-15 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
WO2004002425A2 (fr) * 2002-06-28 2004-01-08 Bio Transplant, Inc. Methodes permettant d'ameliorer l'acceptation d'une greffe par depletion des cellules souches hematopoietiques
AU2004223837C1 (en) 2003-03-24 2012-03-15 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2008067115A2 (fr) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Immunodéplétion sélective de niche de cellules souches endogènes pour greffe
US8540517B2 (en) 2006-11-27 2013-09-24 Pharos Innovations, Llc Calculating a behavioral path based on a statistical profile
WO2011005481A1 (fr) 2009-06-22 2011-01-13 Medimmune, Llc Régions fc de synthèse pour une conjugaison spécifique à un site
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
BR112015018899B1 (pt) 2013-02-08 2023-09-26 Novartis Ag Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira
CN105007950B (zh) * 2013-03-15 2019-01-15 诺华股份有限公司 抗体药物缀合物
EA201691827A1 (ru) * 2014-03-12 2017-01-30 Новартис Аг Конкретные участки для модификации антител с целью получения иммуноконъюгатов
SG11201609462RA (en) * 2014-06-13 2016-12-29 Novartis Ag Auristatin derivatives and conjugates thereof
WO2016020791A1 (fr) * 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
US9938323B2 (en) * 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
EP3280720A4 (fr) * 2015-04-06 2018-12-05 President and Fellows of Harvard College Compositions et procédés s'appliquant au conditionnement non myéloablatif
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
KR20230066647A (ko) * 2016-06-17 2023-05-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법

Also Published As

Publication number Publication date
WO2018116178A1 (fr) 2018-06-28
US20220305134A1 (en) 2022-09-29
MX2019007582A (es) 2019-09-06
CU20190061A7 (es) 2020-03-04
IL267478B1 (en) 2023-03-01
MY193985A (en) 2022-11-04
RU2019122794A3 (fr) 2021-10-12
EP3558389A1 (fr) 2019-10-30
AU2017383458A1 (en) 2019-06-13
IL267478B2 (en) 2023-07-01
JP7622017B2 (ja) 2025-01-27
TW201828991A (zh) 2018-08-16
AU2017383458C1 (en) 2021-08-12
US20250064964A1 (en) 2025-02-27
CU24644B1 (es) 2023-02-13
CO2019006455A2 (es) 2019-06-28
RU2019122794A (ru) 2021-01-22
US11357864B2 (en) 2022-06-14
JP2023015080A (ja) 2023-01-31
JP2020504112A (ja) 2020-02-06
PE20191539A1 (es) 2019-10-23
IL267478A (en) 2019-08-29
AU2017383458B2 (en) 2021-04-29
TWI852077B (zh) 2024-08-11
ECSP19044625A (es) 2019-06-30
IL300567A (en) 2023-04-01
CL2019001745A1 (es) 2019-09-13
BR112019012483A2 (pt) 2020-04-14
KR20190099238A (ko) 2019-08-26
CN110099697A (zh) 2019-08-06
CA3045592A1 (fr) 2018-06-28
US20190321483A1 (en) 2019-10-24
CR20190296A (es) 2019-09-13
PH12019501330A1 (en) 2020-03-02
CN117653740A (zh) 2024-03-08
US12171839B2 (en) 2024-12-24
KR20240093751A (ko) 2024-06-24
JP7181203B2 (ja) 2022-11-30
SA519402188B1 (ar) 2024-01-07
CN110099697B (zh) 2023-11-28
TW202300524A (zh) 2023-01-01
JOP20190155A1 (ar) 2019-06-23
EA201991526A1 (ru) 2020-01-24
TWI778994B (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
MA47231A (fr) Conjugués anticorps-médicament pour l'ablation de cellules souches hématopoïétiques
CY2021018I2 (el) Συζευγμα αντισωματος anti-her2-φαρμακου
MA50755A (fr) Conjugués anticorps-médicaments mult-médicaments
EP3478314A4 (fr) Conjugués pour l'édition de surface cellulaire ciblée
MA51778A (fr) Conjugués anticorps-médicament anti-ccr7
EP2964725A4 (fr) Compositions et procédés pour graver sélectivement du nitrure de titane
EP3370741A4 (fr) Procédés et compositions pour l'édition de gènes dans des cellules souches hématopoïétiques
ME03772B (fr) Conjugués anticorps-médicament spécifiques d'axl pour le traitement du cancer
EP3008170A4 (fr) Cellules dérivées de cellules souches et compositions et procédés pour générer ces cellules
HUE049291T2 (hu) Antitest-hatóanyag konjugátumok és immuntoxinok
HUE040517T2 (hu) Antitest-hatóanyag konjugátumok és immuntoxinok
EP3455344A4 (fr) Cellules souches/progénitrices hématopoïétiques
EP3408372A4 (fr) Aliquotage microfluidique pour l'isolement de cellules individuelles
EP2969373A4 (fr) Plate-forme d'ablation par laser pour cellules solaires
EP3342414A4 (fr) Agent de renforcement de l'atp dans les cellules
EP2976076A4 (fr) Amplificateurs de trail pour tuer sélectivement des cellules cancéreuses
EP3417061A4 (fr) Méthodes et compositions pour l'édition de gènes dans des cellules souches
EP3430060A4 (fr) Conjugués favorisant l'accumulation cellulaire totale
IL260858B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
EP3538098A4 (fr) Conjugués anticorps-médicament
PL3411076T3 (pl) Koniugaty przeciwciało-lek ukierunkowane na uparap
IL279440A (en) Antibody-drug conjugates for hematopoietic stem cell ablation
EP3421589A4 (fr) Composition et procédé pour améliorer l'efficacité de cellules souches
EP3412297A4 (fr) Composition pour inhiber la métastase cancéreuse au moyen de cellules apoptotiques
GB201820864D0 (en) Antibody-drug conjugates